1. A concise review of non-alcoholic fatty liver disease
    Nwe Ni Than et al, 2015, Atherosclerosis CrossRef
  2. Delayed ethanol elimination and enhanced susceptibility to ethanol-induced hepatosteatosis after liver resection
    Xu Liu, 2014, WJG CrossRef
  3. Endocrine causes of nonalcoholic fatty liver disease
    Laura Marino, 2015, WJG CrossRef
  4. Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety
    Elizabeth P. Mills et al, 2017, Therapeutic Advances in Endocrinology CrossRef
  5. Nonalcoholic fatty liver disease: Update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine
    Mazen Noureddin et al, 2015, Exp Biol Med (Maywood) CrossRef
  6. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD)
    Rosa Lombardi et al, 2017 CrossRef
  7. Co-administration effects of aqueous extract of turnip leaf and metformin in diabetic rats
    Moammadmehdi Hassanzadeh-Taheri et al, 2017, Journal of Traditional and Complementary Medicine CrossRef
  8. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
    Naga Chalasani et al, 2018, Hepatology CrossRef
  9. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease
    Ángel Brea et al, 2017, Clínica e Investigación en Arteriosclerosis (English Edition) CrossRef
  10. Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model
    Hui-Hua Chang et al, 2018, Sci Rep CrossRef
  11. Investigation of pharmacological responses to anti-diabetic drugs in female Spontaneously Diabetic Torii (SDT) fatty rats, a new nonalcoholic steatohepatitis (NASH) model
    Yasufumi TORINIWA et al, 2018, The Journal of Veterinary Medical Science CrossRef
  12. Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction
    Sherin E. Mathews et al, 2018, Current Opinion in Endocrinology & Diabetes and Obesity CrossRef
  13. Activation of brown adipose tissue enhances the efficacy of caloric restriction for treatment of nonalcoholic steatohepatitis
    Laurence Poekes et al, 2018, Lab Invest CrossRef
  14. The Future of Nonalcoholic Fatty Liver Disease Treatment
    Khurram Mazhar, 2018, Medical Clinics of North America CrossRef
  15. Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?
    Matteo Tacelli et al, 2018, Pharmaceuticals CrossRef
  16. Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?
    Maria Kalogirou et al, 2018, WJH CrossRef
  17. Metformin: A Candidate Drug for Renal Diseases
    Raphaëlle Corremans et al, 2018, IJMS CrossRef
  18. Management of diabetes mellitus in patients undergoing liver transplantation
    Valeria Grancini et al, 2019, Pharmacological Research CrossRef
  19. Hepatoprotective activity of metformin: A new mission for an old drug?
    Milad Iranshahy et al, 2019, European Journal of Pharmacology CrossRef
  20. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
    Jinhua Yan et al, 2019, Hepatology CrossRef
  21. Metformin: Mechanisms in Human Obesity and Weight Loss
    Armen Yerevanian et al, 2019, Curr Obes Rep CrossRef
  22. null
    Veronika Piskovatska et al, 2019 CrossRef
  23. Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes: a close and developing relationship
    Paula Mayo, 2019, Gastrointestinal Nursing CrossRef
  24. null
    G. Alexander Fleming et al, 2019 CrossRef
  25. Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
    Kyung-Soo Kim et al, 2019, Diabetes Metab J CrossRef
  26. In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium
    Gábor Zsóri et al, 2019, Metabolic Syndrome and Related Disorders CrossRef
  27. Metabolic Targets in Nonalcoholic Fatty Liver Disease
    William P. Esler et al, 2019, Cellular and Molecular Gastroenterology and Hepatology CrossRef
  28. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease
    Hamza El Hadi et al, 2019, IJMS CrossRef
  29. What are the main areas of focus to prevent or treat non‐alcoholic fatty liver disease?
    Asieh Mansour et al, 2019, J Dig Dis CrossRef
  30. Lipotoxicity plays a key role in the development of both insulin resistance and muscle atrophy in patients with type 2 diabetes.
    Ruth C R Meex et al, 2019, Obes Rev CrossRef
  31. Anti-diabetic Drugs and Statins in NAFLD
    Sneha Kothari et al, 2019, Journal of Clinical and Experimental Hepatology CrossRef
  32. Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease.
    Reenam S Khan et al, 2019, Hepatology CrossRef
  33. A Randomised Controlled Trial on the Effectiveness and Adherence of Modified Alternate-day Calorie Restriction in Improving Activity of Non-Alcoholic Fatty Liver Disease
    Muhammad Izzad Johari et al, 2019, Sci Rep CrossRef
  34. Real-world comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive therapy in Russia
    Igor V Maev et al, 2019, BMJ Open Gastroenterol CrossRef
  35. Metformin and metabolic diseases: a focus on hepatic aspects
    Juan Zheng et al, 2015, Front. Med. CrossRef
  36. Metformin ameliorates acetaminophen-induced sub-acute toxicity via antioxidant property
    Shambhoo Sharan Tripathi et al, 2019, Drug and Chemical Toxicology CrossRef
  37. Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?
    G. Targher et al, 2016, Diabetes & Metabolism CrossRef
  38. Where does liver fat go? A possible molecular link between fatty liver and diabetes
    Akihiro Kikuchi et al, 2017, J Diabetes Investig CrossRef
  39. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis—Literature Review
    Abdulrahman Ismaiel et al, 2019, Front. Med. CrossRef
  40. Enfermedad del hígado graso no alcohólico, asociación con la enfermedad cardiovascular y tratamiento (II). Tratamiento de la enfermedad del hígado graso no alcohólico
    Ángel Brea et al, 2017, Clínica e Investigación en Arteriosclerosis CrossRef
  41. A story of metformin-butyrate synergism to control various pathological conditions as a consequence of gut microbiome modification: Genesis of a wonder drug?
    Kunal Maniar et al, 2017, Pharmacological Research CrossRef
  42. Current management of non-alcoholic fatty liver disease
    QUELSON COELHO LISBOA et al, 2016, Rev. Assoc. Med. Bras. CrossRef
  43. Non-alcoholic Fatty Liver Disease: A Clinical Update
    Joseph M Pappachan et al, 2017 CrossRef
  44. Metformin Lactic Acidosis: should we still be afraid?
    Teresa Salvatore et al, 2019, Diabetes Research and Clinical Practice CrossRef
  45. Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction in Patients With Nonalcoholic Fatty Liver Disease
    Milton Packer, 2019, The American Journal of Medicine CrossRef
  46. Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis
    Milica Culafic et al, 2019 CrossRef
  47. SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model
    Atsuo Tahara et al, 2019, Physiol Rep CrossRef
  48. Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer
    Samson Mathews Samuel et al, 2019, Biomolecules CrossRef
  49. Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats
    Myat Theingi Swe et al, 2019 CrossRef
  50. Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice
    Atsuo Tahara et al, 2020, Endocrine Research CrossRef
  51. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management
    Thomas Marjot et al, 2020 CrossRef
  52. The synergistic effect of Citrus bergamia and Cynara cardunculus extracts on vascular inflammation and oxidative stress in non-alcoholic fatty liver disease
    Vincenzo Musolino et al, 2020, Journal of Traditional and Complementary Medicine CrossRef
  53. Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease
    A Reum Choe et al, 2020, BMC Nephrol CrossRef
  54. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
    Yoshio Sumida et al, 2020, IJMS CrossRef
  55. Effect of High-Dose Metformin on the Metabolic Parameters and Functional State of the Liver of Agouti Mice with Melanocortin Obesity
    K. V. Derkach et al, 2020, Adv Gerontol CrossRef
  56. Soluble (pro)renin receptor treats metabolic syndrome in mice with diet-induced obesity via interaction with PPARγ
    Fei Wang et al, 2020 CrossRef
  57. Mutual interaction between endoplasmic reticulum and mitochondria in nonalcoholic fatty liver disease.
    Jin Wang et al, 2020, Lipids Health Dis CrossRef
  58. Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin
    Zeinab A. Saad et al, 2020, Life Sciences CrossRef
  59. Keratin 18-deficiency results in steatohepatitis and liver tumors in old mice: A model of steatohepatitis-associated liver carcinogenesis
    Kira Bettermann et al, 2016, Oncotarget CrossRef
  60. Mechanisms of action of metformin in type 2 diabetes: Effects on mitochondria and leukocyte-endothelium interactions
    Nadezda Apostolova et al, 2020, Redox Biology CrossRef
  61. A comparison of the effects of Stevia extract and metformin on metabolic syndrome indices in rats fed with a high‐fat, high‐sucrose diet
    Tahereh Ranjbar et al, 2020, J Food Biochem CrossRef
  62. Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management
    Maja Cigrovski Berkovic et al, 2020, WJG CrossRef
  63. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease
    John A. Dougherty et al, 2020, Ann Pharmacother CrossRef
  64. The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled trials
    Mohammad Jalali et al, 2020, Pharmacological Research CrossRef
  65. Metabolic liver disease in diabetes – From mechanisms to clinical trials
    Bedair Dewidar et al, 2020, Metabolism CrossRef
  66. Nichtalkoholische Fettlebererkrankung und Typ‑2‑Diabetes
    Jennifer Pützer et al, 2020, Diabetologe CrossRef
  67. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis
    Maryam Mahjoubin-Tehran et al, 2020, Molecular Metabolism CrossRef
  68. Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease
    Suguru Ikeda et al, 2020, Yonago Acta Med. CrossRef
  69. Evolving Role for Pharmacotherapy in NAFLD/NASH
    Suzanna L. Attia et al, 2020, Clin Transl Sci CrossRef
  70. NAFLD in type 2 diabetes mellitus: Still many challenging questions
    Simona Cernea et al, 2020, Diabetes Metab Res Rev CrossRef
  71. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
    Mohammed Eslam et al, 2020, Hepatol Int CrossRef
  72. A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?
    Rebecca K. Vincent et al, 2020, Diabetes Obes Metab CrossRef
  73. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
    Kyung-Soo Kim et al, 2020, Clin Mol Hepatol CrossRef
  74. Metformin Ameliorates Testicular Function and Spermatogenesis in Male Mice with High-Fat and High-Cholesterol Diet-Induced Obesity.
    Chin-Yu Liu et al, 2020, Nutrients CrossRef
  75. METFORMIN USE IN DIABETES PRIOR TO HOSPITALIZATION: EFFECTS ON MORTALITY IN COVID-19
    Jinghong Li et al, 2020, Endocrine Practice CrossRef
  76. null
    Stephen A. Harrison et al, 2018 CrossRef
  77. Da-Chai-Hu Decoction Ameliorates High Fat Diet-Induced Nonalcoholic Fatty Liver Disease Through Remodeling the Gut Microbiota and Modulating the Serum Metabolism
    Huantian Cui et al, 2020, Front. Pharmacol. CrossRef
  78. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials
    Maria-Styliani Kalogirou et al, 2020, Clinics and Research in Hepatology and Gastroenterology CrossRef
  79. Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail
    Mithun Sharma et al, 2020 CrossRef
  80. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
    Kalliopi Pafili et al, 2020, Molecular Metabolism CrossRef
  81. Liraglutide reduces attenuation coefficient as a measure of hepatic steatosis during 16 weeks' treatment in nondiabetic obese patients: A pilot trial
    Xiao Jing Wang et al, 2020, JGH Open CrossRef
  82. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy
    Ying-Xin Xian et al, 2021 CrossRef
  83. Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis
    Chloe Wong et al, 2021, Front. Endocrinol. CrossRef
  84. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions
    Samar H. Gerges et al, 2021, Life Sciences CrossRef
  85. INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES"
    I. I. Dedov et al, 2021, Obes. metabol. CrossRef
  86. The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update
    Reem Abou Assi et al, 2021, Pharmaceuticals CrossRef
  87. Mechanism and application of metformin in kidney diseases: An update
    Anni Song et al, 2021, Biomedicine & Pharmacotherapy CrossRef
  88. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk
    Cyrielle Caussy et al, 2021, Curr Diab Rep CrossRef
  89. Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives
    Christina-Maria Flessa et al, 2021, Curr Obes Rep CrossRef
  90. Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH
    Atsuo Tahara, 2021, European Journal of Pharmacology CrossRef
  91. “One Health” in tendinopathy research: Current concepts
    Roger K. W. Smith et al, 2021, J Orthop Res CrossRef
  92. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective
    Mohammad Said Ramadan et al, 2021, JCM CrossRef
  93. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
    Karn Wijarnpreecha et al, 2021, Clin Mol Hepatol CrossRef
  94. Metformin Modulates T Cell Function and Alleviates Liver Injury Through Bioenergetic Regulation in Viral Hepatitis
    Lanman Xu et al, 2021, Front. Immunol. CrossRef
  95. Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
    Elizabeth M. Lamos et al, 2021, Expert Review of Clinical Pharmacology CrossRef
  96. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
    Agostino Di Ciaula et al, 2021, IJMS CrossRef
  97. null
    Ignazio Grattagliano et al, 2021 CrossRef
  98. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
    Won Euh et al, 2021, Front. Endocrinol. CrossRef
  99. Potential Role of Dexamphetamine in the Treatment of Non-alcoholic Fatty Liver Disease: Hopes and Pitfalls
    CS Gautam et al, 2021 CrossRef
  100. Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention
    Danny Orabi et al, 2021, Cancers CrossRef
  101. Therapeutic regulation of autophagy in hepatic metabolism
    Katherine Byrnes et al, 2021, Acta Pharmaceutica Sinica B CrossRef
  102. Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases
    João V. S. Guerra et al, 2021, Nutrients CrossRef
  103. Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus.
    Jaskamal Padda et al, 2021, Cureus CrossRef
  104. The promise of the gut microbiome as part of individualized treatment strategies
    Daniel A. Schupack et al, 2021, Nat Rev Gastroenterol Hepatol CrossRef
  105. NAFLD in the Elderly
    Saleh A Alqahtani et al, 2021, CIA CrossRef
  106. Evaluation of the reciprocal interaction between hepatic steatosis and type 2 diabetes: a comparative analysis with respect to anti-diabetic treatment, glycemic control, renal and hepatic function
    Teslime Ayaz et al, 2021, Int J Diabetes Dev Ctries CrossRef
  107. Insulin resistance and insulin sensitizing agents
    Lucia Mastrototaro et al, 2021, Metabolism CrossRef
  108. Does vitamin D replacement therapy cause a regression in fatty liver disease? A case control study of comparison of vitamin D and other common therapy modalities
    Vusal ABDURAHMANOV et al, 2021 CrossRef
  109. Metformin intoksikasyonuna sekonder gelişen akut böbrek hasari ve laktik asidoz
    Halil AYDAR et al, 2021 CrossRef
  110. A RANDOMISED, PROSPECTIVE, PARALLELAND OPEN LABEL STUDY TO COMPARE EFFICACY AND SAFETY OF METFORMIN PLUS ROSUVASTATIN AND GLIMEPIRIDE PLUS ROSUVASTATIN IN PATIENTS OF COEXISTING NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND TYPE 2 DIABETES MELLITUS (T2DM)
    Prabhsimran kaur et al, 2021, ijsr CrossRef
  111. Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels
    Kanokwan Pinyopornpanish et al, 2021, Gut and Liver CrossRef
  112. Metformin Causes Hepato-renal Dysfunctions in Obese Male Rats
    Sabry Ali El-Naggar et al, 2021, Braz. arch. biol. technol. CrossRef
  113. Exploring the Gamut of Receptor Tyrosine Kinases for Their Promise in the Management of Non-Alcoholic Fatty Liver Disease
    Sayali Bhave et al, 2021, Biomedicines CrossRef
  114. A High-Fat Diet Attenuates AMPK α1 in Adipocytes to Induce Exosome Shedding and Nonalcoholic Fatty Liver Development In Vivo
    Chenghui Yan et al, 2021 CrossRef
  115. Adherence to lifestyle modification in patients with nonalcoholic fatty liver disease
    K. A. Andreev et al, 2022, Bûll. sib. med. CrossRef
  116. Different sites of actions make different responses to thiazolidinediones between mouse and rat models of fatty liver
    Chihiro Ebihara et al, 2022, Sci Rep CrossRef
  117. The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
    Yasser Fouad et al, 2022, Saudi J Gastroenterol CrossRef
  118. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction‐associated fatty liver disease
    Wah‐Kheong Chan et al, 2022, J of Gastro and Hepatol CrossRef
  119. HA-20 prevents hepatocyte steatosis in metabolic-associated fatty liver disease via regulating Ca2+ relative signalling pathways
    Jie Wang et al, 2022, European Journal of Pharmacology CrossRef
  120. Review article: Role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know
    A. Sidney Barritt et al, 2022, Aliment Pharmacol Ther CrossRef
  121. Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity
    Yi-ni Cao et al, 2022, Journal of Ethnopharmacology CrossRef
  122. Er-Chen Decoction Alleviates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Rats through Remodeling Gut Microbiota and Regulating the Serum Metabolism
    Jing Miao et al, 2022, Evidence-Based Complementary and Alternative Medicine CrossRef
  123. A Clinical Perspective of the Multifaceted Mechanism of Metformin in Diabetes, Infections, Cognitive Dysfunction, and Cancer
    Elaine Chow et al, 2022, Pharmaceuticals CrossRef
  124. Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome
    Iliana Doycheva et al, 2022, Fertility and Sterility CrossRef
  125. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
    Kenneth Cusi et al, 2022, Endocrine Practice CrossRef
  126. Prevention of Hepatocellular Carcinoma
    Kerstin Schütte et al, 2016, Gastrointest Tumors CrossRef
  127. The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications
    Rossella Palma et al, 2022, JCM CrossRef
  128. Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease
    Raghu Ramanathan et al, 2022, IJMS CrossRef
  129. Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
    Eun-Jung Rhee, 2022, Endocrinol Metab CrossRef
  130. Metformin use and the risk of total knee replacement among diabetic patients: a propensity-score-matched retrospective cohort study
    Francisco T. T. Lai et al, 2022, Sci Rep CrossRef
  131. Evidence-based management of patients with nonalcoholic fatty liver disease
    Minal Patel, 2022 CrossRef
  132. Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents
    Kyung-Soo Kim, 2022, J Korean Diabetes CrossRef
  133. A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes
    Azam Doustmohammadian et al, 2022, Front. Med. CrossRef
  134. The spike of SARS-CoV-2 promotes metabolic rewiring in hepatocytes
    Maria Mercado-Gómez et al, 2022, Commun Biol CrossRef
  135. Nonalcoholic Fatty Liver Disease and Its Complex Relation with Type 2 Diabetes Mellitus—From Prevalence to Diagnostic Approach and Treatment Strategies
    Cosmina-Theodora Diaconu et al, 2022, JCM CrossRef
  136. null
    Maria Apostolopoulou et al, 2022 CrossRef
  137. Reversal of High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease by Metformin Combined with PGG, an Inducer of Glycine N-Methyltransferase
    Ming-Hui Yang et al, 2022, IJMS CrossRef
  138. LC–MS/MS Method Assay for Simultaneous Determination of the Apixaban and Metformin in Rat Plasma: Assessment of Pharmacokinetic Drug–Drug Interaction Study
    Libin Wang et al, 2022 CrossRef
  139. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways
    Olufunto O. Badmus et al, 2022 CrossRef
  140. Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology
    Yuanshe Huang et al, 2022 CrossRef
  141. The crosstalk between insulin resistance and nonalcoholic fatty liver disease/metabolic dysfunction-associated fatty liver disease: a culprit or a consequence?
    Dae-Jeong Koo et al, 2022, CPP CrossRef
  142. null
    Georgios Sfikas et al, 2022 CrossRef
  143. Correlation between long-term use of metformin and incidence of NAFLD among patients with type 2 diabetes mellitus: A real-world cohort study
    Kuang-Hua Huang et al, 2022, Front. Endocrinol. CrossRef
  144. Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease
    V. T. Ivashkin et al, 2022, Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii CrossRef
  145. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Non-alcoholic Fatty Liver Disease (NAFLD)
    Ajay Duseja et al, 2022, Journal of Clinical and Experimental Hepatology CrossRef
  146. Therapeutic role of Artemether in the prevention of hepatic steatosis through miR‐34a‐5p/PPARα pathway
    Li Chen et al, 2022, Drug Development Research CrossRef
  147. Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different
    Stephen D. H. Malnick et al, 2022, IJMS CrossRef
  148. Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials
    Joel Yeh Siang Chen et al, 2022, IJMS CrossRef
  149. Management of metabolic-associated fatty liver disease: The diabetology perspective
    Mohammad Sadiq Jeeyavudeen et al, 2023, World J Gastroenterol CrossRef
  150. Repurposing of Drugs for Cardiometabolic Disorders: An Out and Out Cumulation
    Rufaida Wasim et al, 2023, Horm Metab Res CrossRef
  151. Metformin enhances neural precursor cells migration and functional recovery after ischemic stroke in mice
    Liang Zhang et al, 2023, Exp Brain Res CrossRef
  152. NAFLD and type 2 diabetes: A practical guide for the joint management
    Idoia Genua et al, 2022, Gastroenterología y Hepatología CrossRef
  153. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
    Li Rong et al, 2023, Front. Endocrinol. CrossRef
  154. Metabolic Role of Autophagy in the Pathogenesis and Development of NAFLD
    Lingxuan An et al, 2023, Metabolites CrossRef